Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT2 | O75908 | 1/20 | 1.00 |
| ▸ | ACAT1 | P24752 | 1/20 | 1.00 |
| ▸ | SOAT1 | P35610 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 7/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | PLK1 | P53350 | 1/20 | 0.37 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.36 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eflucimibe SCHEMBL668292 | 1.00 | SOAT2 (1.00) | SOAT2ACAT1SOAT1ALDH1A1CYP2C9 | |
| Eflucimibe SCHEMBL29427708 | 1.00 | SOAT2 (1.00) | SOAT2ACAT1SOAT1ALDH1A1CYP2C9 | |
| Eflucimibe SCHEMBL8041449 | 0.91 | SOAT2 (0.82) | SOAT2ACAT1SOAT1ALDH1A1CYP2C9 | |
| SCHEMBL5900907 | 0.89 | SOAT2 (0.80) | SOAT2ACAT1SOAT1ALDH1A1CYP2C9 | |
| SCHEMBL5900910 | 0.89 | SOAT2 (0.80) | SOAT2ACAT1SOAT1ALDH1A1CYP2C9 | |
| SCHEMBL8079670 | 0.89 | SOAT1 (0.79) | SOAT2ACAT1SOAT1ALDH1A1CYP2C9 | |
| SCHEMBL8416087 | 0.88 | SOAT2 (0.78) | SOAT2ACAT1SOAT1ALDH1A1CYP2C9 | |
| SCHEMBL13269963 | 0.87 | SOAT2 (0.76) | SOAT2ACAT1SOAT1ALDH1A1CYP2C9 | |
| SCHEMBL13193425 | 0.86 | SOAT2 (0.75) | SOAT2ACAT1SOAT1ALDH1A1CYP2C9 | |
| SCHEMBL13249165 | 0.85 | SOAT2 (0.73) | SOAT2ACAT1SOAT1ALDH1A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190247397-A1 | COMBINATORY TREATMENT STRATEGIES OF CANCER BASED ON RNA POLYMERASE I INHIBITION | THE JOHNS HOPKINS UNIVERSITY | 2019-08-15 | — | — | US | claimed |
| EP-3515448-A1 | COMBINATORY TREATMENT STRATEGIES OF CANCER BASED ON RNA POLYMERASE I INHIBITION | The Johns Hopkins University (US) | 2019-07-31 | — | — | EP | claimed |
| WO-2018057834-A1 | COMBINATORY TREATMENT STRATEGIES OF CANCER BASED ON RNA POLYMERASE I INHIBITION | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-03-29 | — | — | WO | claimed |
| US-20050192245-A1 | Medicinal composition for treating arteriosclerosis | SANKYO COMPANY, LIMITED (JP) | 2005-09-01 | — | — | US | claimed |
| EP-1555032-A1 | MEDICINAL COMPOSITION FOR TREATING ARTERIOSCLEROSIS | Sankyo Company, Limited (JP) | 2005-07-20 | — | — | EP | claimed |
| US-12303508-B2 | Combinatory treatment strategies of cancer based on RNA polymerase I inhibition | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-05-20 | — | — | US | disclosed |
| US-11911469-B2 | Combination of ACAT1 inhibitor and checkpoint antibody for treating cancer | Center for Excellence in Molecular Cell Science, Chinese Academy of Scienes (CN) | 2024-02-27 | — | — | US | disclosed |
| EP-3515448-B1 | COMBINATORY TREATMENT STRATEGIES OF CANCER BASED ON RNA POLYMERASE I INHIBITION | UNIV JOHNS HOPKINS (US) | 2023-07-05 | — | — | EP | disclosed |
| US-11571400-B2 | ACAT1 inhibitors for treating cancer | CENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) | 2023-02-07 | — | — | US | disclosed |
| US-10925885-B2 | Thyromimetics for the treatment of fatty liver diseases | METABASIS THERAPEUTICS, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-10420781-B2 | Thyroid hormone receptor agonist and use thereof | METABASIS THERAPEUTICS INC. (US) | 2019-09-24 | — | — | US | disclosed |
| US-20190247397-A1 | COMBINATORY TREATMENT STRATEGIES OF CANCER BASED ON RNA POLYMERASE I INHIBITION | THE JOHNS HOPKINS UNIVERSITY | 2019-08-15 | — | — | US | disclosed |
| WO-2004035552-A1 | ALPHA-PHENYL ACETANILIDE DERIVATIVES HAVING AN ACAT INHIBITING ACTIVITY AND THE THERAPEUTIC APPLICATION THEREOF | PIERRE FABRE MEDICAMENT (FR) | 2004-04-29 | — | — | WO | disclosed |
| EP-1377545-A1 | ANILIDE AND CYCLODEXTRIN COMPLEXES, THEIR PREPARATION AND THEIR USE AS MEDICINE IN PARTICULAR FOR TREATING DYSLIPIDEMIAE | PIERRE FABRE MEDICAMENT (FR) | 2004-01-07 | — | — | EP | disclosed |
| EP-1377545-A1 | ANILIDE AND CYCLODEXTRIN COMPLEXES, THEIR PREPARATION AND THEIR USE AS MEDICINE IN PARTICULAR FOR TREATING DYSLIPIDEMIAE | PIERRE FABRE MEDICAMENT (FR) | 2004-01-07 | — | — | EP | disclosed |
| WO-2003106435-A1 | FUSED-RING PYRIMIDIN-4(3H)-ONE DERIVATIVES, PROCESSES FOR THE PREPARATION AND USES THEREOF | SANKYO COMPANY, LIMITED (JP) | 2003-12-24 | — | — | WO | disclosed |
| WO-2002083632-A1 | ANILIDE AND CYCLODEXTRIN COMPLEXES, THEIR PREPARATION AND THEIR USE AS MEDICINE IN PARTICULAR FOR TREATING DYSLIPIDEMIAE | PIERRE FABRE MEDICAMENT (FR) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083632-A1 | ANILIDE AND CYCLODEXTRIN COMPLEXES, THEIR PREPARATION AND THEIR USE AS MEDICINE IN PARTICULAR FOR TREATING DYSLIPIDEMIAE | PIERRE FABRE MEDICAMENT (FR) | 2002-10-24 | — | — | WO | disclosed |
| EP-0874812-B1 | NOVEL 2,3,5-TRIMETHYL-4-HYDROXY ANILIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTICAL USE THEREOF | PF MEDICAMENT (FR) | 2000-04-05 | — | — | EP | disclosed |
| US-5990173-A | ANTICHOLESTEROL AGENTS; TREATING ATHEROSCLEROSIS; ENZYME INHIBITORS OF ACYLCOENZYME A:CHOLESTEROL ACYLTRANSFERASE (ACAT) | PIERRE FABRE MEDICAMENT (FR) | 1999-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10420781-B2 | Thyroid hormone receptor agonist and use thereof | THRB, THRA, TSHR | SOAT2 533/4885ACAT1 781/4885SOAT1 384/4885 |
| US-10925885-B2 | Thyromimetics for the treatment of fatty liver diseases | TSHR, THRA, FABP1 | SOAT2 426/4885ACAT1 210/4885SOAT1 463/4885 |
| US-11571400-B2 | ACAT1 inhibitors for treating cancer | ACAT2, ACAT1, CEPT1 | SOAT2 384/4885ACAT1 2/4885SOAT1 149/4885 |
| US-11911469-B2 | Combination of ACAT1 inhibitor and checkpoint antibody for treating cancer | CD274, PDCD1, PDCD4 | SOAT2 3131/4885ACAT1 7/4885SOAT1 1835/4885 |
| US-12303508-B2 | Combinatory treatment strategies of cancer based on RNA polymerase I inhibition | ACAT1, PARP1, POLRMT | SOAT2 524/4885ACAT1 1/4885SOAT1 238/4885 |
| US-20190247397-A1 | COMBINATORY TREATMENT STRATEGIES OF CANCER BASED ON RNA POLYMERASE I INHIBITION | ACAT1, PARP1, POLRMT | SOAT2 524/4885ACAT1 1/4885SOAT1 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.